The screening of bioactive microbial products provided chemists with interesting materials for the structure studies and the design of new chemical syntheses, and the results of these studies promoted the progress of the study on structure-activ~t y relationships. Moreover, the study of genetics and biosyntheses of microbial
1. 2-Deoxystreptamine-containing compounds p r o d u c e d s t r a i n a n d i t s m u t a n t : Kanamycin A (R1,R2=~, R~=OH, R q =~~2 .
R 5 =~~2 ) , Kanamycin B (R1 .R2'H. R3,R4'NH2, R5'NH2), Kanamycin C (R1 ,R2=H. R3=NH2. R4=OH, R5=NH2), NKlOOl (R1,R2=H, R3,R4,~5'OH), NK1012-1 (R,,R2=H, R3,R4=NH2, R5=OH), NK1013-1 (Rl=CH3C0 a n d R2=H o r R1' H a n d R2=CH3C0, R3,R4=NH2, R5=CH3CONH), NK1013-2 (RlzCH3C0 a n d R2=H o r R1=H a n d R2=CH3C0, R , R =NH2, R5=NH2) 3 4 'and widely distributed among various strains, species, genera, families and orders of microorganisms. In fact, the presence of such a gene has been confirmed: the ability of a strain to produce kanamycin was eliminated by acriflavine treatment and most kanamycin-nonproducing mutants thus obtained produced kanamycin in culture media to which 2-deoxystreptamine was It inhibits the growth of various bacteria and exhibits an antitumor action against mouse leukemia L-1210. As shown in Fig. 2 , its structure may be called 3-&-3-dichloromethylactinobolin. The structure relationships between these two antibiotics suggest the possible involvement of a same gene in the biosynthesis of their characteristic dicyclic part.
Adriamycin (Fig. 3 ) is an antitumor antibiotic which has been widely used in the treatment of various types of human cancer and its strong anticancer activity Stimulates the study of anthracycline antibiotics in detail. The study of the 9 biosynthesis of anthracycline antibiotics has shown that aklavinone or its precursor (9-demethoxycarbonyl-9-carboxyaklavinone) is an biosynthetic intermediate common to pyrromycin, aclacinomycin, cinerubin, daunomycin, adriamycin etc. (Fig.   3 ). The addition of aklavinone to culture media caused the production of these antibiotics by their nonproducing mutants, although ~lumauerovk &.lo reported that aklavinone was not the intermediate to daunomycin. The results of these biosynthetic studies indicate a wide distribution of a gene involved in the biosynthesis of aklavinone or its precursor among various species of streptomyces.
On the basis of the structures ofeachgroupof antibioticsand recentstudiesontheir HCTEROCYCLES, Vol 13, 1979 genetics, it can be proposed as follows: (1) genes involved in the biosynthesis of characteristic structural parts or characteristic biosynthetic intermediates of each group of secondary metabolites have been generated and the products like 2-deoxystreptamine etc. are synthesized; (2) these products produced in cells have no cytotoxicity and are transformed or modified to final products by reactions of enzymes which are produced by following the control of other genes and the final products are released extracellularly; (3) in cells of different strains, the products are modified to different final products; (4) the wide distribution of these genes involved in the biosynthesis of characteristic structural parts among microorganisms suggests that in some or many cases these genes generated in a strain have been transferred to cells of other strains. In the case that they lie on plasmids, it is possible that they have been transferred into other cells of other strains or different species where the products are further differently modified. 9
The author1' first noticed a possible involvement of plasmids in the biosynthesis of some antibiotics, and Hopwood 12'13 proved the involvement of a plasmid in the biosynthesis of methylenomycin, The structure of methylenomycin A , Z-methylenecyclopentane-3-one-4,5-epoxy-4,5-dimethyl-l-carboxylic acid, 1 4 " ' suggests its possible biosynthesis by a multienzyme system. Leupeptin (Fig. 4) . that is, acetyl(or propiony1)-leucyl-leucyl-argininal found by the author,'= inhibits trypsin, plasmin, papain and cathepsin B. Trypsin hydrolyzes the arginyl bond, and leupeptin which contains argininal inhibits such endopeptidases. This aldehyde structure of inhibiting serine-thiol proteases was first found in leupeptin.
17
Leupeptin was found in culture filtrates of many strains belonging to more than 18 species of streptomyces. This indicates that a characteristic gene involved in leupeptin biosynthesis is widely distributed among various strains of various different species of streptomyces. It suggests that this gene might lie on a plasmid and have been transferred to other strains. In fact, this was confirmed. 18
Leupeptin is biosynthesized by the reduction of leupeptin acid (acetylleucylleucylarginine), and an enzyme complex which catalyzes the synthesis of leupeptin acid can be extracted from homogenates of a leupeptin-producing strain. In a reaction mixture containing ATP, acetate, leucine and arginine, the enzyme complex catalyzes the synthesis of leupeptin acid starting from the synthesis of acetylleucine.19 On the other hand, the ability to produce leupeptin is eliminated by acriflavine treatment of a leupeptin-producing strain, and most leupeptinnonproducing mutants thus obtained do not produce the enzyme complex which catalyzes the synthesis of leupeptin acid. The ability to produce leupeptin can be transferred from a leupeptin-producing strain to a leupeptin-nonproducing mutant by conjugation. This indicates that the gene involved in the biosynthesis of the enzyme complex lies on a plasmid.
L e u p e p t i n A n t i p a i n . .
Chymostatin E l a s t a t i n a l
P e p s t a t i n Phosphoramidon Phosphoramidone inhibits thermolysin and other metalloendopeptidases. As later described, inhibitors of aminopeptidases have also been found in streptomyces culture filtrates. gulosel during passing through the cell membrane and is released extracellularly.
As already described, leupeptin acid which is a characteristic biosynthetic intermediate to leupeptin has been confirmed to be synthesized by a multienzyme system.
Gramicidins and bacitracin are known to be synthesized by a multienzyme system specific to each of them. As described above, all specific multienzyme systems HFIEROCYCLES, Vol 13, 1979 were suggested to be involved in the hiosynthesis of almost all protease inhibitors and bleomycin. Extending these to the biosynthesis of other types of microbial products, it seems to be interesting to examine whether a multienzyme system is involved in the biosynthesis of a characteristic structural part of a secondary metabolite or its precursor. For instance, it may be an interesting study to examine whether 2-deoxystreptamine or its precursor is synthesized by an enzyme complex, that is, by a multienzyme system.
As descrihed in this paragraph, it has been shown that secondary metaboliteswhich have widely varied structures are produced by microorganisms, and the reason why so many compounds are produced has been analyzed up to the understandahle step.
Therefore, if an exact screening method is established, it is reasonable to search for microbial products which are fit to the purpose. The results of this study will supply new bioactive chemical structures.
SMALL MOLECULAR IMMUNOMODUIJLTORS PRODUCED BY MICROORGANISMS
In cancer patients the cell immunity is decreased. Therefore, it is thought that compounds enhancing cell immunity should enhance the effect of any cancer treatment. It is also thought that immunity-enhancing agents will be useful in the treatment of resistant infections in immunodeficient patients. Therefore, the author extended the study of enzyme inhibitors to the screening of microbial products which enhanced or decreased immune responses.
D i k e t o c o r i o l i n B B e s t a t i n Forpheni c i n e

Amastatin E s t e r a s t i n F i g . 6. M i c r o b i a l products a f f e c t i n g immune responses
In this study, first, the author found that coriolin group antibiotics 26.27 and its derivative (diketocoriolin B) as shown ih Fig The author searched for microbial culture filtrates which inhibited the hydrolysis of N-arginyl-6-aminonaphthalene by aminopeptidase B prepared from rat liver in a reaction mixture containing 0.50 ml of pH 7.0, 0.1 M Tris-HC1, 0.25 ml of 2 mM arginyl-0-aminonaphthalene, 0.24 ml of distilled water with or without a diluted culture filtrate which was heated for 3 minutes at 100°C and 0.01 ml of the enzyme solution. The hydrolyzed 8-minonaphthalene was determined by reading the optical
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density at 525 nm after addition of 1.0 ml of Fast Granet GBC 12-methyl-4-1(2-methylphenyl)azo]benzene diazonium chloride solutionl. In this study, we discovered bestatin which inhibited aminopeptidase B and leucine aminopeptidase. 31
The structure of bestatin (Fig. 6 ) was determined to be 3-amino-2-hydroxy-4-phenylbutyryl-L-leucine. The 2S,3R stereochemistry of the unusual amino acid was determined by X-ray crystal analysis of the hydrobromide of the methyl ester of 3-amino-2-hydroxy-4-phenylbutyric acid.32 The oxazolidone of this amino acid prepared by alkali treatment of its N-benzyloxycarbonyl derivative showed 4.0 Hz as the coupling constant of vicinal protons which conformed to the --structure. 3 3
Thus, it was shown that Shiha's oxazolidone method for determination of stereochemistry of u-amino-0-hydroxy acids could be applied also to the determination of 0-amino-a-hydroxy acids.
All 8 stereoisomers of bestatin were synthesized and the 2S configuration was found to be the key structure for the activity to inhibit aminopeptidases. Four Esterase is located on the cell surface and an inhibitor named esterastin (Fig. 6 ) was found in a culture filtrate of streptomyces.39 The intraperitoneal injection of 62 ug/mouse or more suppressed both hypersensitivity and antibody formation.
It contains a 0-lactone group which is found only very rarely among natural products. Immune suppressive agents may be useful in the treatment of autoimmune diseases. In Table 1 , kinetic constants of bestatin, amastatin, forphenicine and esterastin are described. Ki value of esterastin is very small compared with those of others and indicates a very strong binding of esterastin with esterase. Although it has not yet been studied, the action of esterastin in suppressing immune responses may be related to its strong binding to the cell surface. As described above, the microbial compounds found by the screening of culture filtrates which inhibited the enzymes on the cell surface has given those which enhance or decrease immune responses, and new bioactive structures were thus discovered.
Table 1. Km and K i o f amastatin, b e s t a t i n , forphenicine and e s t e r a s t i n and the types o f t h e i r i n h i b i t i o n I n h i b i t o r s Enzvmes
DEVELOPMENT OF EFFECTIVE DERIVATIVES AND ANALOGS
Following the isolation and the structure determination of a useful bioactive compound, it is natural for chemists to attempt to synthesize this compound and its derivatives or analogs. These studies are promoted by practical necessity.
Kanamycin (Fig. 1) --50'51 were successful in the total chemical syntheses of streptomycin and dihydrostreptomycin. The most common enzyme which causes the resistance to streptomycin is 3"-0-adenylyl or 3"-0-phosphotransferase which transfers AMP or phosphate to the 3-hydroxyl group of the N-methyl-L-glucosamine moiety. 5 2 . 4 2 s,
~r n e z a w a~~ synthesized 3"-deoxydihydrostreptomycin. This derivative inhibits the growth of resistant strains except for Pseudomonas aeruginosa. Based on this result, the resistance of Pseudomonas aeruginosa to this derivative was found to be due to the 6-0-phosphotransferase which transferred phosphate to the 6-hydroxyl group of the streptamine It is now possible to synthesize streptomycin derivatives active against resistant strains.
If the mechanism of action is elucidated on the structural level, as in the case Of aminoglycoside antibiotics, active structures can be predicted and the compounds which have the expected activity can be synthesized. From this aspect, the author is trying to develop bleomycin derivatives. Bleomycin found by the is used in the treatment of squamous cell carcinoma, Hodgkin's lymphoma and testis tumors.
In the presence of ferrous ion, bleomycin reacts with DNA. The reaction results in strand scissions of DNA. ESR study of bleomycin metal complexes has elucidated the stereochemical structure of the bleomycin-ferrous complex (Fig. 7) . On the basis of this structure and the quenching the fluorescence of bleomycin by the addition of polyn~cleotides,~' it has been proposed that the bithiazole moiety of bleomycin binds to the guanine moiety of DNA and the oxygen molecule which binds to the ferrous ion of bleomycin-ferrous complex is activated and reacts with the deoxyribose moiety of DNA.~' Cupric ion binds very strongly to bleomycin. reducing agents such as cysteine etc. and the cuprous ion thus formed is transferred to a cellular protein which binds to cuptous ion; copper-free bleomycin thus produced in cells undergoes the action of bleomycin hydrolase which hydrolyzes the a-aminocarboxamide group of the pyrimidoblamyl moiety;pK of the a-amino group of bleomycin shifts from 7.4 to 9.3 after the hydrolysis by this enzyme and this amino group of pK 9.3 cannot be involved in the coordination to produce ferrous complex at neutral pH and thus bleomycin is inactivated by this enzyme reaction; copper-free bleomycin which escaped from the action of bleomycin hydrolase reaches the nucleus and binds with DNA and ferrous ion and causes DNA strand scission, or bleomycin-copper complex which escaped from the action of reducing agents reaches the nucleus, binds with DNA, the cupric ion is reduced and replaced with ferrous ion and DNA is fragmented. 59
Therapeutic effect of bleomycin on squamous cell carcinoma is due to a low content of bleomycin hydrolase and a high concentration of.this antibiotic in this tumor.
On the basis of this behavior & I ? and the action mechanism of bleomycin, it is possible to predict the structure of the derivatives which will show a different antitumor spectrum. Derivatives which are resistant to bleomycin hydrolase may show a wider antitumor spectrum. The modification of the a-amino group of HETEROCYCLES, Yo1 13, 1979
the o-aminocarboxamide group or the modification of the amide group of the aaminocarboxamide moiety gives derivatives which are resistant to bleomycin hydrolase and inhibit experimental animal tumors.
In the case of antitumor antibiotics, chemical derivation or the screening by fermentation is successfully developing, affording derivatives and analogs which have lower toxicity than the parent compounds.
Bleomycins which contain two or more guanidine groups or an amidine group in the terminal m i n e have a strong renal toxicity (Fig. 5) . Therefore, the mixture of bleomycins consisting mainly of 70% A2 and 25% BZ has been used clinically. The mixture showed the strongest action against Ehrlich carcinoma compared with any single bleomycin shown in Fig. 5 . The side effect of bleomycin used at present appears in the lung after the administration of it in large amounts. The degree of pulmonary toxicity was found to be different among various bleomycins which were different in their terminal amine moiety.
The main structural part common to all bleom~cins is called bleomycinic acid. By searching for enzymes which hydrolyzed bleom~cin to bleomycinic acid, an enzyme which hydrolyzed bleomycin BZ to bleomycinic acid and agmatine was found in a fungus belonging to Fusarium species.60 This enzyme is specific to acylagmatine and hydrolyzes not only bleomycin BZ but also acetyl, propionyl and benzoylagmatine. A chemical method has also been developed to give bleomycinic acid. 61
The treatment of the copper complex of bleomycin demethyl-A2 with cyanogen bromide gives bleomycinic acid as follows:
In this reaction the a-amino group of the pyrimidoblamyl moiety is protected by copper chelation. An amine or an alcohol in the reaction mixture replaces the 3 -benzoylaminopropanol group and the bleomycin containing this amine or alcohol is obtained.
By the chemical method, the following bleomycins which cannot be prepared by fermentation have been prepared:
A s already described, the side effect of bleomycin which limits the use of its large dosage is pulmonary toxicity. Therefore, a bleomycin which has lower pulmonary toxicity than the present bleomycin and which has the same or a stronger activity can exhibit a stronger therapeutic effect on human cancer sensitive to bleomycin treatment. A method of testing pulmonary toxicity has been established by using aged mice and bleomycins which have low pulmonary toxicity has been selected. Some examples are shown in Table 2 . Among these bleomycins shown in Table 2 , the pulmonary toxicity of A 5 0 3 3 was first tested clinically and was conflrrned to have a lower pulmonary toxicity than the present bleomycin. It suggested ii" 0 0.05
that the pulmonary toxicity test using aged mice gave a right selection of useful bleomycins. Among bleomycins shown in Table 2 , bleomycin PEP which is called pepleomycin has been studied in most detail: pepleomycin shows a stronger therapeutic effect against head, neck and skin carcinoma than the present bleomycin and has a lower pulmonary toxicity. This stimulates further studies of various bleomycins in the purpose to find more effective and useful ones.
A s described in the first paragraph of this paper, adriamycin is a very useful HETEROCYCID, Vol 13, 1979
cancer chemotherapeutic agent. The side effect of this drug is the delayed cardiac toxicity due to the degeneration of heart muscles. The degree of this toxicity is measured by electronmicroscopy of heart muscles after the administration of anthracycline antibiotics to hamsters, rats or rabbits. The results of this test indicated that aclacinomycin (Fig. 3) The author found eight daunomycinone glycosides in a culture filtrate of a daunomycin-producing straln and elucidated their structures. Four of them were new 4 ' -0-glycosidic derivatives of daunomycin and named haumycins Al, A2, B1 and 8 2 ( Fig.   81 .64 The stereochemistry of baumycins B1 and 82 was determined by x-ray crystal analysis.65 Among these baumycins, A1 showed a stronger therapeutic effect than adriamycin against mouse leukemia L-1210. However, the yield of baumycin A1 by fermentation was very small: moreover, the tests using different samples repeated by other laboratories did not give the same result. Therefore, the author decided to synthesize 4'-0-glycosidic derivatives of daunomycin and adriamycin. Among the derivatives thus synthesized, one of the 4'-0-tetrahydropyranyladriamycins showed a stronger effect than adriamycin in the effect on mouse leukemia L -1 2 1 0 .~~ The author sent this compound to Dr. ath he in Paris who had proved the low cardiac toxicity of aclacinomycin. He found that this derivative had a significantly lower cardiac toxicity than adria~n~cin.~' Its cardiac toxicity was reversible and its grade was similar to aclacinomycin which had never caused delayed cardiac toxicity in clinical study.
As described above, organic chemistry has a predominant role in the development of effective derivatives and analogs. But generally, except for the cases of aminoglycosides active against resistant infections, at present, it is still impossible to predict the effective structures,'and the success is dependent upon careful tests of the compounds ~~nthesized'randomly or under some hypotheses. Although in the future it may become to predict the active structures, at present findings of active structures by screening, chemical studies of their actions and synthesis of their derivatlv&s and analogs are the general approach to the compounds useful in the treatment of diseases difficult to cure.
FUTURE ASPECTS
In concluding this paper, it may be necessary to discuss about the role of organic chemistry in the progress of bioactive compounds or the role of bioactive microbial secondary metabolites in the progress of organic chemistry. As described above, except for bleomycin which is an unusual glycopeptide of about 1.500 molecular weight, and which contains a very unusual amino acid such as pyrimidoblamic acid, the structures of all small molecular microbial products were rapidly elucidated and most of them were chemically synthesized. This indicates a great role of organic chemistry in the study of microbial products and a rapid progress of organic chemistry in the last 20 years. This progress will continue further together with the development of equipments. In the future, the isolation, extraction, purification and structure determination will be completed much faster than at present. It may be possible to establish an organization which elucidate structures rapidly upon the receipt of orders. Moreover, the chemical synthesis of new structure compounds will become easier and easier and the result will give abundant information on structure-activity relationships. Moreover, accumulation of these information and skillfulness of computers will become useful to design the chemical synthesis of active agents. However, it seems to take many years to reach the era where we can predict the bioactive structures exactly. Although HETEROCYCLES, Val 13. 1979 there was a great progress in protein chemistry and the structure of an important mlecular part of an inhibitor of kininase was successfully predicted, in general it is almost impossible even to predict all possible structures of a specific inhibitor of an enzyme. Therefore, in the present situation, the screening of microbial products is still one of the most important research routes leading to new bioactive structures. Although it has often been said that microorganisms in nature produce antibiotics to suppress the growth of others, as described in this paper, besides antibiotics various bioactive compounds which have no antimicrobial aktivity have been obtained from microorganisms. Therefore, in the case that a quantitative simple screening method is established, there is a high possibility tb find compounds which have the expected bioactivity. The studies of action mechanisms are now shifting over from the molecular level, that is, to the conformational level, and the results in the future will contribute to the prediction of active derivatives. On the other hand, chemical synthesis of derivatives which lack hydrogen-bonding groups partially or totally may give the most simple active structures. In the case of compounds such as bleomycin, adriamycin etc. which are useful but which have characteristic toxicity, the study of their derivatives and analogs is going to provide us with more effective compounds.
Although it will take many years for biochemistry to clarify the differences between all kinds of cells in human body and their relationships, biochemistry of disease processes is rapidly progressing on the enzymic level, and is helping to design many useful screening methods.
Therefore, also in the future, the screening of bioactive microbial product will dig up new bioactive structures and promote the progress of organic chemistry for structure determination, chemical syntheses and structure-activity relationships.
